Kolexia
Brugieres Laurence
Oncologie médicale
Gustave-Roussy
Villejuif, France
294 Activités
167 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Ostéosarcome Lymphome à grandes cellules anaplasiques Hépatoblastome Tumeurs du foie Prédisposition génétique à une maladie Récidive tumorale locale Tumeurs osseuses Tumeurs du cerveau

Industries

Bayer
2 collaboration(s)
Dernière en 2022
Eisai
1 collaboration(s)
Dernière en 2020
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Essai Clinique (Unicancer)   26 février 2024
Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival.
European journal of cancer (Oxford, England : 1990)   01 février 2024
SARCOME13: Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response)
Essai Clinique (Unicancer)   01 février 2024
OS2006 : Protocole de Traitement Des ostéosarcomes de l'Enfant, de l'Adolescent et de l'Adulte Comportant
Essai Clinique (Chugai)   09 janvier 2024
ctDNA quantification improves estimation of outcomes in patients with high grade osteosarcoma: a translational study from the OS2006 trial.
Annals of oncology : official journal of the European Society for Medical Oncology   22 décembre 2023
Preneoplastic liver colonization by 11p15.5 altered mosaic cells in young children with hepatoblastoma.
Nature communications   06 novembre 2023
Circulating Tumor DNA (ctDNA) for Plasma Genotyping and Disease Monitoring in ALK-Positive Anaplastic Lymphoma (ALK+ALCL): A Proof of Concept Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Neurofibromatosis type 1 mosaicism in patients with constitutional mismatch repair deficiency.
Journal of medical genetics   29 septembre 2023
Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial.
European journal of cancer (Oxford, England : 1990)   17 juillet 2023
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
Science translational medicine   28 juin 2023